Treatment
of multiple sclerosis with anti-measles cow colostrum
Ebina T, Sato
A, Umezu K, Aso H, Ishida N, Seki H, Tsukamoto T, Takase S, Hoshi
S, Ohta M.
Previous virological
and immunological studies have suggested that multiple sclerosis (MS)
is an auto-immune disease triggered by a virus infection. In order
to inhibit the growth of measles virus in the patient's jejunum, we
obtained an IgA-rich cow colostrum containing anti-measles lactoglobulin
resistant to proteases.
This colostrum
was orally administered to patients with MS to investigate its effect
on the course of the disease. Measles-positive antibody colostrum
was orally administered every morning to 15 patients with MS at a
daily dosage of 100 ml for 30 days. Similarly, measles-negative antibody
(less than 8) control colostrum was orally administered to 5 patients.
As a clinical
assessment, disability scores developed by the International Federation
of Multiple Sclerosis Societies were used. As a result, of 7 high
NT titre (512-5120) anti-measles colostrum recipients 5 patients improved
and 2 remained unchanged. Among 8 low NT titre (8-32) anti-measles
colostrum recipients 5 patients improved and 3 remained unchanged.
However, of 5
negative NT titre (less than 8) colostrum recipients 2 patients remained
unchanged and 3 worsened. No side-effects were observed in colostrum
recipients.
These findings
suggest the efficacy of orally administered anti-measles colostrum
in improving the condition of MS patients (P less than 0.05).
Articles
59
